Literature DB >> 26285813

Androgen actions via androgen receptor promote PTEN inactivation induced uterine cancer.

Jaesung Peter Choi1, Reena Desai1, Yu Zheng1, Mu Yao1, Qihan Dong1, Geoff Watson1, David J Handelsman2, Ulla Simanainen1.   

Abstract

Haploinsufficient inactivating phosphatase and tensin homolog (Pten) mutations cause Cowden syndrome, an autosomal dominant risk genotype for hormone dependent reproductive cancers. As androgen actions mediated via the androgen receptor (AR) supports uterine growth and may modify uterine cancer risk, we hypothesized that a functional AR may increase PTEN inactivation induced uterine cancer. To test the hypothesis, we compared the PTEN knockout (PTENKO) induced uterine pathology in heterozygous PTENKO and combined heterozygous PTEN and complete AR knockout (PTENARKO) female mice. PTENKO induced uterine pathology was significantly reduced by AR inactivation with severe macroscopic uterine pathology present in 21% of PTENARKO vs 46% of PTENKO at a median age of 45 weeks. This could be due to reduced stroma ERα expression in PTENARKO compared to PTENKO uterus, while AR inactivation did not modify PTEN or P-AKT levels. Unexpectedly, while progesterone (P4) is assumed protective in uterine cancers, serum P4 was significantly higher in PTENKO females compared to WT, ARKO, and PTENARKO females consistent with more corpora lutea in PTENKO ovaries. Serum testosterone and ovarian estradiol were similar between all females. Hence, our results demonstrated AR inactivation mediated protection against PTENKO induced uterine pathology and suggests a potential role for antiandrogens in uterine cancer prevention and treatment.
© 2015 Society for Endocrinology.

Entities:  

Keywords:  PTEN; androgen receptor; androgens; mouse; uterine cancer

Mesh:

Substances:

Year:  2015        PMID: 26285813     DOI: 10.1530/ERC-15-0203

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  3 in total

1.  The Flavonoid Apigenin Is a Progesterone Receptor Modulator with In Vivo Activity in the Uterus.

Authors:  Matthew Dean; Julia Austin; Ren Jinhong; Michael E Johnson; Daniel D Lantvit; Joanna E Burdette
Journal:  Horm Cancer       Date:  2018-05-07       Impact factor: 3.869

2.  Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Authors:  Filipe Correia Martins; Dominique-Laurent Couturier; Anna Paterson; Anthony N Karnezis; Christine Chow; Tayyebeh M Nazeran; Adekunle Odunsi; Aleksandra Gentry-Maharaj; Aleksandra Vrvilo; Alexander Hein; Aline Talhouk; Ana Osorio; Andreas D Hartkopf; Angela Brooks-Wilson; Anna DeFazio; Anna Fischer; Arndt Hartmann; Brenda Y Hernandez; Bryan M McCauley; Chloe Karpinskyj; Christiani B de Sousa; Claus Høgdall; Daniel G Tiezzi; Esther Herpel; Florin Andrei Taran; Francesmary Modugno; Gary Keeney; Gregg Nelson; Helen Steed; Honglin Song; Hugh Luk; Javier Benitez; Jennifer Alsop; Jennifer M Koziak; Jenny Lester; Joseph H Rothstein; Jurandyr M de Andrade; Lene Lundvall; Luis Paz-Ares; Luis Robles-Díaz; Lynne R Wilkens; Maria J Garcia; Maria P Intermaggio; Marie-Lyne Alcaraz; Mary A Brett; Matthias W Beckmann; Mercedes Jimenez-Linan; Michael Anglesio; Michael E Carney; Michael Schneider; Nadia Traficante; Nadja Pejovic; Naveena Singh; Nhu Le; Peter Sinn; Prafull Ghatage; Ramona Erber; Robert Edwards; Robert Vierkant; Roberta B Ness; Samuel Leung; Sandra Orsulic; Sara Y Brucker; Scott H Kaufmann; Sian Fereday; Simon Gayther; Stacey J Winham; Stefan Kommoss; Tanja Pejovic; Teri A Longacre; Valerie McGuire; Valerie Rhenius; Weiva Sieh; Yurii B Shvetsov; Alice S Whittemore; Annette Staebler; Beth Y Karlan; Cristina Rodriguez-Antona; David D Bowtell; Ellen L Goode; Estrid Høgdall; Francisco J Candido Dos Reis; Jacek Gronwald; Jenny Chang-Claude; Kirsten B Moysich; Linda E Kelemen; Linda S Cook; Marc T Goodman; Peter A Fasching; Robin Crawford; Suha Deen; Usha Menon; David G Huntsman; Martin Köbel; Susan J Ramus; Paul D P Pharoah; James D Brenton
Journal:  Br J Cancer       Date:  2020-06-18       Impact factor: 7.640

3.  Evaluating the efficacy of enzalutamide and the development of resistance in a preclinical mouse model of type-I endometrial carcinoma.

Authors:  Christopher S Koivisto; Melodie Parrish; Santosh B Bonala; Soo Ngoi; Adrian Torres; James Gallagher; Rebekah Sanchez-Hodge; Victor Zeinner; Georges J Nahhas; Bei Liu; David E Cohn; Floor J Backes; Paul J Goodfellow; Helen M Chamberlin; Gustavo Leone
Journal:  Neoplasia       Date:  2020-08-17       Impact factor: 5.715

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.